(2023). Predictive Value of sCD93 in The Diagnosis of Bronchial Asthma. The Egyptian Journal of Hospital Medicine, 93(1), 7857-7861. doi: 10.21608/ejhm.2023.331765
. "Predictive Value of sCD93 in The Diagnosis of Bronchial Asthma". The Egyptian Journal of Hospital Medicine, 93, 1, 2023, 7857-7861. doi: 10.21608/ejhm.2023.331765
(2023). 'Predictive Value of sCD93 in The Diagnosis of Bronchial Asthma', The Egyptian Journal of Hospital Medicine, 93(1), pp. 7857-7861. doi: 10.21608/ejhm.2023.331765
Predictive Value of sCD93 in The Diagnosis of Bronchial Asthma. The Egyptian Journal of Hospital Medicine, 2023; 93(1): 7857-7861. doi: 10.21608/ejhm.2023.331765
Predictive Value of sCD93 in The Diagnosis of Bronchial Asthma
Background: Studying asthma is no longer focused on symptoms and pulmonary functions but it expands to the underlying cellular changes. The membrane-associated glycoprotein CD93 is an emerging biomarker for inflammation in many inflammatory and immune-mediated diseases including asthma. Objectives: We aimed to evaluate the value of serum sCD93 and its mRNA expression level as a non-invasive biomarker for bronchial asthma. Patients and methods: This case control study was conducted to assess serum and mRNA expression levels of sCD93 in 40 bronchial asthma patients and 40 age- and gender-matched healthy controls. Results: Both serum and mRNA levels of sCD93 were significantly higher in asthmatic patients (18.4 ± 2.4 ng/ml and 1.16 ± 0.57 folds) than healthy controls (11.2 ± 1.3 ng/ml and 0.711 ± 0.35 folds) (P < 0.001 each). Serum sCD93 was 95% sensitive and 80% specific in diagnosing asthma at cut-off value ≥ 13.3 ng/ml. While CD93 mRNA expression was 70% sensitive and 60% specific in diagnosing asthma at cut-off value ≥ 0.81 fold. Conclusion: sCD93 is a valuable non-invasive biomarker for bronchial asthma.
View on SCiNiTO
Top